Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention: A Randomized Clinical Trial

• Autores: Nelly R. Mugo, Ting Hong, Connie Celum, Deborah Donnell
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 312, Nº. 4, 2014, págs. 362-371
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Importance Antiretroviral preexposure prophylaxis (PrEP), using tenofovir disoproxil fumarate (TDF) and combination emtricitabine/tenofovir disoproxil fumarate (FTC+TDF), is efficacious for prevention of human immunodeficiency virus (HIV) acquisition. PrEP could reduce periconception HIV risk, but the effect on pregnancy outcomes is not well defined.

    Objective To assess pregnancy incidence and outcomes among women using PrEP during the periconception period.